These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20872746)

  • 21. Expression of osteoclastogenic factor transcripts in osteoblast-like UMR-106 cells after exposure to FGF-23 or FGF-23 combined with parathyroid hormone.
    Teerapornpuntakit J; Wongdee K; Krishnamra N; Charoenphandhu N
    Cell Biol Int; 2016 Mar; 40(3):329-40. PubMed ID: 26694880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Butyrate Stimulates Histone H3 Acetylation, 8-Isoprostane Production, RANKL Expression, and Regulated Osteoprotegerin Expression/Secretion in MG-63 Osteoblastic Cells.
    Chang MC; Chen YJ; Lian YC; Chang BE; Huang CC; Huang WL; Pan YH; Jeng JH
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30562925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.
    Fu Q; Jilka RL; Manolagas SC; O'Brien CA
    J Biol Chem; 2002 Dec; 277(50):48868-75. PubMed ID: 12364326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.
    Choudhary S; Goetjen A; Estus T; Jacome-Galarza CE; Aguila HL; Lorenzo J; Pilbeam C
    J Biol Chem; 2016 Feb; 291(8):3882-94. PubMed ID: 26703472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts.
    Boabaid F; Berry JE; Koh AJ; Somerman MJ; McCcauley LK
    J Periodontol; 2004 Sep; 75(9):1247-54. PubMed ID: 15515341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
    Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.
    Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG
    Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
    Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
    J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
    Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
    J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminothiazoles inhibit osteoclastogenesis and PGE
    Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
    J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption.
    Radeff JM; Nagy Z; Stern PH
    Exp Cell Res; 2001 Aug; 268(2):179-88. PubMed ID: 11478844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells.
    Kariya Y; Honma M; Hanamura A; Aoki S; Ninomiya T; Nakamichi Y; Udagawa N; Suzuki H
    J Bone Miner Res; 2011 Apr; 26(4):689-703. PubMed ID: 20939018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
    Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
    Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.